不同剂量瑞舒伐他汀对急性脑梗死患者的效果

Effect of Different Dosages of Rosuvastatin on Patients with Acute Cerebral Infarction

目的研究在不同剂量下,瑞舒伐他汀对急性脑梗死(ACI)的影响。方法选取2019年1月至2023年6月郑州市第一人民医院收治的60例ACI患者进行回顾性分析,以不同用药方式划分为两组,研究组(n=30)给予20 mg瑞舒伐他汀,参照组(n=30)给予10 mg瑞舒伐他汀,对比两组患者治疗效果,治疗前后神经功能损伤程度、日常生活活动指数(ADL-Barthel)、炎性因子[白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)]及基质金属蛋白酶9(MMP-9)、血浆胎盘生长因子水平(PLGF)水平。结果研究组治疗有效率高于参照组,差异有统计学意义(P<0.05);治疗前两组美国国立卫生研究院卒中量表(NIHSS)、ADL-Barthel评分差异无统计学意义(P>0.05),治疗6周、12周后,两组ADL-Barthel评分均升高,NIHSS评分均降低,且研究组ADL-Barthel评分高于参照组,研究组NIHSS评分低于参照组,差异均有统计学意义(P<0.05);治疗前两组炎性因子水平差异无统计学意义(P>0.05),治疗6周、12周后,两组IL-6,TNF-α,hs-CRP炎性因子水平均降低,且研究组炎性因子水平均低于参照组,差异均有统计学意义(P<0.05);治疗前两组MMP-9、PLGF水平差异无统计学意义(P>0.05),治疗6周、12周后,两组MMP-9、PLGF水平均降低,且研究组MMP-9、PLGF水平均低于参照组,差异均有统计学意义(P<0.05)。结论ACI患者在常规对症治疗基础上联合应用较大剂量瑞舒伐他汀,能够改善患者神经功能与MMP-9、PLGF水平,提高患者日常生活质量,值得临床借鉴。

Objective To investigate the effect of rosuvastatin at different dosages on acute cerebral infarction(ACI).Methods A retrospective analysis was conducted on 60 patients with ACI admitted to The First People's Hospital of Zhengzhou City from January 2019 to June 2023.The patients were divided into two groups based on different medication regimens.The study group(n=30)received 20 mg of rosuvastatin,while the control group(n=30)received 10 mg of rosuvastatin.The therapeutic effects,degree of neurological functional impairment,activities of daily living(ADL-Barthel),inflammatory factors[interleukin-6(IL-6),high-sensitivity C-reactive protein(hs-CRP),tumor necrosis factor-alpha(TNF-α)],matrix metalloproteinase-9(MMP-9),and plasma placental growth factor(PLGF)levels were compared between the two groups.Results The effective rate of treatment in the study group was higher than that in the control group,with statistically significant differences(P<0.05).There were no statistically significant differences in the National Institutes of Health Stroke Scale(NIHSS)and ADL-Barthel scores between the two groups before treatment(P>0.05).However,after 6 and 12 weeks of treatment,the ADL-Barthel score was higher and the NIHSS score was lower in the study group compared to the control group, with statistically significant differences (P < 0.05). There were no statistically significant differences in the levels of inflammatory factors between the two groups before treatment (P > 0.05). However, after 6 and 12 weeks of treatment, the levels of IL-6, TNF-α, and hs-CRP decreased in both groups, with the levels being lower in the study group compared to the control group, with statistically significant differences (P < 0.05). There were no statistically significant differences in MMP-9 and PLGF levels between the two groups before treatment (P > 0.05). However, after 6 and 12 weeks of treatment, the levels of MMP-9 and PLGF decreased in both groups, with the levels being lower in the study group compared to the control group, with statistically significant differences (P < 0.05).Conclusion In patients with ACI, the combination of a higher dose of rosuvastatin with routine symptomatic treatment can improve neurological function, MMP-9, and PLGF levels, and enhance the quality of daily life, which is worthy of clinical reference.